文献速递慢性肾脏病

运动训练对非透析CKD患者肌肉质量及血浆肌生成抑制素的影响:RENEXC随机对照试验子研究

Muscle mass and plasma myostatin after exercise training: a substudy of Renal Exercise (RENEXC)-a randomized controlled trial.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

这项RENEXC试验预设子研究纳入151例非透析依赖CKD患者(平均实测GFR 23±8 mL/min/1.73 m2),随机分配至力量训练或平衡联合耐力训练组,干预12个月。结果显示运动训练似可预防肌少症并维持肌肉质量,平衡组下肢及全身瘦体重显著增加,两组血浆肌生成抑制素均显著升高且力量组更明显,但肌少症患病率及体成分组间无显著差异。

要点

  • 12个月运动训练似可预防非透析CKD患者肌少症并维持肌肉质量。
  • 平衡组下肢及全身瘦体重显著增加,力量组无变化,组间无差异。
  • 两组血浆肌生成抑制素均显著升高,力量组升高更明显。

核心结论

  • 运动训练似乎能有效预防非透析依赖CKD患者的肌少症并维持肌肉质量。
  • 血浆肌生成抑制素在CKD患者肌肉质量及体能中的作用尚需进一步研究。

研究设计与样本

  • RENEXC随机对照试验的预设子研究,共纳入151例非透析依赖患者,平均实测GFR 23±8 mL/min/1.73 m2,不限年龄或合并症。
  • 患者随机分配至力量训练组或平衡联合耐力训练组,干预12个月;体成分用双能X线吸收法测定,血浆肌生成抑制素用酶联免疫吸附试剂盒分析。

主要发现

  • 12个月后肌少症患病率不变;平衡组下肢及全身瘦体重显著增加,力量组无变化;两组全身脂肪量均显著下降。
  • 肌少症或体成分无显著组间差异;两组血浆肌生成抑制素均显著升高,组间差异显著利于力量组。
  • 基线时血浆肌生成抑制素与肌肉质量及体能显著正相关,12个月后这些关系减弱。

临床怎么用

  • 对非透析依赖CKD患者,可考虑将运动训练(力量或平衡联合耐力)作为预防肌少症、维持肌肉质量的干预策略。
  • 血浆肌生成抑制素不宜单独作为CKD患者肌肉质量或体能的监测指标,其临床解读需结合更多研究。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcopenia increases as renal function declines and is associated with higher morbidity and mortality. Myostatin is a negative regulator of muscle growth. Its expression in response to exercise is unclear. In this prespecified substudy of the Renal Exercise (RENEXC) trial, we investigated the effects of 12 months of exercise training on sarcopenia, muscle mass and plasma myostatin and the relationships between physical performance, muscle mass and plasma myostatin. METHODS: A total of 151 non-dialysis-dependent patients (average measured glomerular filtration rate 23 ± 8 mL/min/1.73 m2), irrespective of age or comorbidity, were randomly assigned to either strength or balance in combination with endurance training. Body composition was measured with dual-energy X-ray absorptiometry. Plasma myostatin was analysed using enzyme-linked immunosorbent assay kits. RESULTS: After 12 months, the prevalence of sarcopenia was unchanged, leg and whole-body lean mass increased significantly in the balance group and was unchanged in the strength group. Whole fat mass decreased significantly in both groups. There were no significant between-group differences in sarcopenia or body composition. Plasma myostatin levels increased significantly in both groups, with a significant difference in favour of the strength group. Plasma myostatin was significantly positively related to muscle mass and physical performance at baseline, but these relationships were attenuated after 12 months. CONCLUSIONS: Exercise training seems to be effective in preventing sarcopenia and maintaining muscle mass in non-dialysis-dependent patients with chronic kidney disease (CKD). However, the role of plasma myostatin on muscle mass and physical performance in patients with CKD warrants further study.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Zhou Y, Hellberg M, Hellmark T, et al. Muscle mass and plasma myostatin after exercise training: a substudy of Renal Exercise (RENEXC)-a randomized controlled trial. Nephrol Dial Transplant. 2021. PMID: 31848626. doi:10.1093/ndt/gfz210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。